PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma

NCT07641010 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: PD-1+JAK1i
DRUG: PD-1

Sponsor

Shanghai Jiao Tong University School of Medicine